Molecular recognition in the human immunodeficiency virus capsid and antiviral design

Virus Research

Volumn 169, Issue 2, 2012, Pages 388-410

  Bocanegra, Rebeca ^a   Rodríguez Huete, Alicia ^a   Fuertes, Miguel ángel ^a   del álamo, Marta ^a   Mateu, Mauricio G ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antiviral agent; Capsid; Human immunodeficiency virus; Interfacial inhibitor; Molecular recognition; Peptide

Indexed keywords

ANKYRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM BINDING PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CAPSID PROTEIN; DENDRIMER; GLYCINE DERIVATIVE; HYDRAZONE DERIVATIVE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PEPTIDE DERIVATIVE; PF 3450074; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG DESIGN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR RECOGNITION; MOLECULAR STABILITY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; VIRUS CAPSID; VIRUS MORPHOGENESIS; VIRUS MORPHOLOGY; VIRUS MUTATION; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; HIV CORE PROTEIN P24; HIV-1; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84868609925     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.06.016     Document Type: Review

References (169)

1. Abdurahman S., Végvari á., Youssefi M., Levi M., Höglund S., Andersson E., Horal P., Svennerholm B., Balzarini J., Vahlne A. Activity of the small modified amino acid α-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity. Antimicrobial Agents and Chemotherapy 2008, 52:3737-3744.
2. Adamson C.S., Freed E.O. Human immunodeficiency virus type 1 assembly, release and maturation. Advances in Pharmacology 2007, 55:347-397.
3. Adamson C.S., Jones I.M. The molecular basis of HIV capsid assembly-five years of progress. Reviews in Medical Virology 2004, 14:107-121.
4. Adamson C.S., Salzwedel K., Freed E.O. Virus maturation as a novel HIV-1 therapeutic target. Expert Opinion on Therapeutic Targets 2009, 13:895-908.
5. Ako-Adjei D., Johnson M.C., Vogt V.M. The retroviral capsid domain dictates virion size, morphology and coassembly of gag into virus-like particles. Journal of Virology 2005, 79:13463-13472.
6. Andersson E., Horal P., Jejcic A., Höglund S., Balzarini J., Vahlne A., Svennerholm B. Glycine amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide. Antimicrobial Agents and Chemotherapy 2005, 49:40-44.
7. Alcaraz L.A., del álamo M., Barrera F.N., Mateu M.G., Neira J.L. Flexibility in HIV-1 assembly subunits: solution structure of the monomeric C-terminal domain of the capsid protein. Biophysical Journal 2007, 93:1264-1276.
8. Alcaraz L.A., del álamo M., Mateu M.G., Neira J.L. Structural mobility of the monomeric C-terminal domain of the HIV-1 capsid protein. FEBS Journal 2008, 275:3299-3311.
9. Arhel N. Revisiting HIV-1 uncoating. Retrovirology 2010, 7:96.
10. Bailey G.D., Hyun J.K., Mitra A.K., Kingston R.L. Proton-linked dimerization of a retroviral capsid protein initiates capsid assembly. Structure 2009, 17:737-748.
11. Barbaro G., Scozzafava A., Mastrolorenzo A., Supuran C.T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Current Pharmaceutical Design 2005, 11:1805-1843.
12. Barklis E., Alfadhli A., McQuaw C., Yalamuri S., Still A., Barklis R.L., Kukull B., López C.S. Characterization of the in vitro HIV-1 capsid assembly pathway. Journal of Molecular Biology 2009, 387:376-389.
13. Bartonova V., Igonet S., Sticht J., Glass B., Habermann A., Vaney M.-C., Sehr P., Lewis J., Rey F.A., Kräusslich H.-G. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. Journal of Biological Chemistry 2008, 283:32024-32033.
14. Bharat T.A.M., Davey N.E., Ulbrich P., Riches J.D., de Marco A., Rumlova M., Sachse C., Ruml T., Briggs J.A.G. Structure of the immature retroviral capsid at 8Å resolution by cryo-electron microscopy. Nature 2012, 10.1038/nature11169.
15. Bhattacharya S., Zhang H., Cowburn D., Debnath A.K. Novel structures of self-associating stapled peptides. Biopolymers 2012, 97:253-264.
16. Bhattacharya S., Zhang H., Debnath A.K., Cowburn D. Solution structure of a hydrocarbon staple peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid. Journal of Biological Chemistry 2008, 283:16274-16278.
17. Bieniasz P.D. The cell biology of HIV-1 virion genesis. Cell Host & Microbe 2009, 5:550-558.
18. Blair W.S., Pickford C., Irving S.L., Brown D.G., Anderson M., Bazin R., Cao J., Ciaramella G., Isaacson J., Jackson L., Hunt R., Kjerrstrom A., Nieman J.A., Patick A.K., Perros M., Scott A.D., Whitby K., Wu H., Butler S.L. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathogens 2010, 6:e1001220.
19. Bocanegra R., Nevot M., Doménech R., López I., Abián O., Rodríguez-Huete A., Cavasotto C.N., Velázquez-Campoy A., Gómez J., Martínez M.A., Neira J.L., Mateu M.G. Rationally designed interfacial peptides are efficient in vitro inhibitorss of HIV-1 capsid assembly with antiviral activity. PloS ONE 2011, 6:e23877.
20. Bogan A.A., Thorn K.S. Anatomy of hot spots in protein interfaces. Journal of Molecular Biology 1998, 280:1-9.
21. Bon Homme M., Carter C., Scarlata S. The cysteine residues of HIV-1 capsid regulate oligomerization and cyclophilin A-induced changes. Biophysical Journal 2005, 88:2078-2088.
22. Bonsor D.A., Sundberg E.J. Dissecting protein-protein interactions using directed evolution. Biochemistry 2011, 50:2394-2402.
23. Borsetti A., öhagen å., Göttlinger H.G. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. Journal of Virology 1998, 72:9313-9317.
24. Braun K., Frank M., Pipkorn R., Reed J., Spring H., Debus J., Didinger B., von der Lieth C.-W., Wiessler M., Waldeck W. HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytes. International Journal of Medical Sciences 2008, 5:230-239.
25. Briggs J.A., Kräusslich H.-G. The molecular architecture of HIV. Journal of Molecular Biology 2011, 410:491-500.
26. Briggs J.A.G., Riches J.D., Glass B., Forster F., Kräusslich H.-G., Fuller S. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure 2006, 14:15-20.
27. Briggs J.A.G., Riches J.D., Glass B., Bartonova V., Zanetti G., Kräusslich H.-G. Structure and assembly of immature HIV. Proceedings of the National Academy of Sciences of United States of America 2009, 106:11090-11095.
28. Briggs J.A.G., Simon M.N., Gross I., Kräusslich H.-G., Fuller S.D. Structural organization of authentic, mature HIV-1 virions and cores. EMBO Journal 2003, 22:1707-1715.
29. Briggs J.A.G., Simon M.N., Gross I., Kräusslich H.-G., Fuller S.D., Vogt V.M., Johnson M.C. The stoichiometry of Gag protein in HIV-1. Nature Structural & Molecular Biology 2004, 11:672-675.
30. Briones M.S., Chow S.A. A new functional role of HIV-1 integrase during uncoating of the viral core. Immunologic Research 2010, 48:14-26.
31. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Research 2010, 85:1-18.
32. Byeon I.J., Meng X., Jung J., Zhao G., Yang R., Ahn J., Shi J., Concel J., Aiken C., Zhang P., Gronenborn A.M. Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function. Cell 2009, 139:780-790.
33. Campbell S., Rein A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. Journal of Virology 1999, 73:2270-2279.
34. Campbell S., Vogt V.M. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. Journal of Virology 1995, 69:6487-6497.
35. Campbell S., Fisher R.J., Towler E.M., Fox S., Issaq H.J., Wolfe T., Phillips L.R., Rein A. Modulation of HIV-like particle assembly in vitro by inositol phosphates. Proceedings of the National Academy of Sciences of United States of America 2001, 98:10875-10879.
36. Cao J., Isaacson J., Patick A.K., Blair W.S. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes Vif as an antiviral target. Antimicrobial Agents and Chemotherapy 2005, 49:3833-3841.
37. Cardone G., Purdy J.G., Cheng N., Craven R.C., Steven A.C. Visualization of a missing link in retrovirus capsid assembly. Nature 2009, 457:694-699.
38. Carlson L.-A., Briggs J.A.G., Glass B., Riches J.D., Simon M.N., Johnson M.C., Müller B., Grünewald K., Kräusslich H.-G. Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host & Microbe 2008, 4:592-599.
39. Chen B., Tycko R. Structural and dynamical characterization of tubular HIV-1 capsid protein assemblies by solid state nuclear magnetic resonance and electron microscopy. Protein Science 2010, 19:716-730.
40. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
41. Cornvik T., Dahlroth S.L., Magnusdottir A., Herman M.D., Knaust R., Ekberg M., Nordlund P. Colony filtration blot: a new screening method for soluble protein expression in Escherichia coli. Nature Methods 2005, 2:507-509.
42. Cortines J.R., Monroe E.B., Kang S., Prevelige P.E. A retroviral chimeric capsid protein reveals the role of the N-terminal β-hairpin in mature core assembly. Journal of Molecular Biology 2011, 410:641-652.
43. Cunningham B.C., Wells J.A. High-resolution epitope mapping of hGH-receptor interactions by alanine scanning mutagenesis. Science 1989, 244:1081-1085.
44. Curreli F., Zhang H., Zhang X., Pyatkin I., Zagorodnikov V., Altieri A., Debnath A.K. Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid. Bioorganic and Medicinal Chemistry 2011, 19:77-90.
45. Dahlroth S.L., Nordlund P., Cornvik T. Colony filtration blotting for screening soluble expression in Escherichia coli. Nature Protocols 2006, 1:253-258.
46. Darlix J.-L., Garrido J.L., Morellet N., Mély Y., de Rocquigny H. Properties, functions and drug targeting of the multifunctional nucleocapsid protein of the human immunodeficiency virus. Advances in Pharmacology 2007, 55:299-346.
47. De Clercq E. Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery 2002, 1:13-25.
48. De Clercq E. Antiviral drugs in current clinical use. Journal of Clinical Virology 2004, 30:115-133.
49. de Marco A., Davey N.E., Ulbrich P., Phillips J.M., Lux V., Riches J.D., Fuzik T., Ruml T., Kräusslich H.-G., Vogt V.M., Briggs J.A.G. Conserved and variable features of Gag structure and arrangement in immature retrovirus particles. Journal of Virology 2010, 84:11729-11736.
50. de Marco A., Müller B., Glass B., Riches J.D., Kräusslich H.-G., Briggs J.A.G. Structural analysis of HIV-1 maturation using cryoelectron tomography. PLoS Pathogens 2010, 6:e1001215.
51. De Rocquigny H., Shvadchak V., Avilov S., Dong C.Z., Dietrich U., Darlix J.-L., Mély Y. Targeting the viral nucleocapsid protein in anti-HIV-1 therapy. Mini-Reviews in Medicinal Chemistry 2008, 8:24-35.
52. del álamo M., Mateu M.G. Electrostatic repulsion, compensatory mutations, and long-range non-additive effects at the dimerization interface of the HIV capsid protein. Journal of Molecular Biology 2005, 345:893-906.
53. del álamo M., Neira J.L., Mateu M.G. Thermodynamic dissection of a low affinity protein-protein interface involved in human immunodeficiency virus assembly. Journal of Biological Chemistry 2003, 278:27923-27929.
54. del álamo M., Rivas G., Mateu M.G. Effect of macromolecular crowding agents on human immunodeficiency virus type 1 capsid protein assembly in vitro. Journal of Virology 2005, 79:14271-14281.
55. DeLano, W.L., 2002. DeLano Scientific LLC, San Carlos, CA, USA. PyMOL molecular graphics system on World Wide Web URL: http://www.pymol.org/.
56. Doménech R., Abián O., Bocanegra R., Correa J., Sousa-Herves A., Riguera R., Mateu M.G., Fernandez-Megia E., Velázquez-Campoy A., Neira J.L. Dendrimers as potential inhibitors of the dimerization of the capsid protein of HIV-1. Biomacromolecules 2010, 11:2069-2078.
57. Doménech R., Bocanegra R., González-Muñiz R., Gómez J., Mateu M.G., Neira J.L. Larger helical populations in peptides derived from the dimerization helix of capsid protein of HIV-1 results in peptide binding toward regions other than the " hotspot" interface. Biomacromolecules 2011, 12:3252-3264.
58. Doménech R., Bocanegra R., Velázquez-Campoy A., Neira J.L. The isolated major homology region of the HIV-1 capsid protein is mainly unfolded in solution and binds to the intact protein. Biochimica et Biophysica Acta 2011, 1814:1269-1278.
59. Domingo E. RNA virus evolution and the control of viral disease. Progress in Drug Research 1989, 33:93-133.
60. Domingo E., Biebricher C., Eigen M., Holland J.J. Quasispecies and RNA Virus Evolution: Principles and Consequences 2001, Landes Biosciences, Austin.
61. Dorfman T., Bukovsky A., öhagen å., Höglund S., Göttlinger H.G. Functional domains of the capsid protein of human immunodeficiency virus type 1. Journal of Virology 1994, 68:8180-8187.
62. Douglas C.C., Thomas D., Lanman J., Prevelige P.E. Investigation of N-terminal domain charged residues on the assembly and stability of HIV-1 CA. Biochemistry 2004, 43:10435-10441.
63. Du S., Betts L., Yang R., Shi H., Concel J., Ahn J., Aiken C., Zhang P., Yeh J.I. Structure of the HIV-1 full-length capsid protein in a conformationally trapped unassembled state induced by small-molecule binding. Journal of Molecular Biology 2010, 406:371-386.
64. Edwards T.A., Wilson A.J. Helix-mediated protein-protein interactions as targets for intervention using foldamers. Amino Acids 2011, 41:743-754.
65. Ehrlich L.S., Agresta B.E., Carter C.A. Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. Journal of Virology 1992, 66:4874-4883.
66. Ehrlich L.S., Liu T., Scarlata S., Chu B., Carter C. HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophysical Journal 2001, 81:586-594.
67. Fader L.D., Bethrell R., Bonneau P., Bös M., Bousquet Y., Cordingley M.G., Coulombe R., Deroy P., Faucher A.-M., Gagnon A., Goudreau N., Grand-Maître C., Guse I., Hucke O., Kawai S.H., Lacoste J.-E., Landry S., Lemke C.T., Malenfant E., Mason S., Morin S., OóMeara J., Simoneau B., Titolo S., Yoakim C. Discovery of a 1,5-dihydrobenzo[b][1.4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. Bioorganic and Medicinal Chemistry 2011, 21:398-404.
68. Fletcher S., Hamilton A.D. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. Journal of the Royal Society Interface 2006, 3:215-233.
69. Forshey B.M., von Schwedler U., Sundquist W.I., Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. Journal of Virology 2002, 76:5667-5677.
70. Fuller S.D., Wilk T., Gowen B.E., Kräusslich H.-G., Vogt V.M. Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle. Current Biology 1997, 7:729-738.
71. Gamble T.R., Yoo S., Vajdos F.F., von Schwedler U.K., Worthylake D.K., Wang H., McCutcheon J.P., Sundquist W.I., Hill C.P. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 1997, 278:849-853.
72. Ganser B.K., Li S., Klishko V.Y., Finch J.T., Sundquist W.I. Assembly and analysis of conical models for the HIV-1 core. Science 1999, 283:80-83.
73. Ganser-Pornillos B.K., Cheng A., Yeager M. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 2007, 131:70-79.
74. Ganser-Pornillos B.K., von Schwedler U.K., Stray K.M., Aiken C., Sundquist W.I. Assembly properties of the human immunodeficiency virus type 1 CA protein. Journal of Virology 2004, 78:2545-2552.
75. Ganser-Pornillos B.K., Yeager M., Pornillos O. Assembly and architecture of HIV. Advances in Experimental Medicine and Biology 2012, 726:441-465.
76. Ganser-Pornillos B.K., Yeager M., Sundquist W.I. The structural biology of HIV assembly. Current Opinion in Structural Biology 2008, 18:203-217.
77. Gao M., Skolnick J. The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation. Proceedings of the National Academy of Sciences of United States of America 2012, 109:3784-3789.
78. Garzón M.T., Lidón-Moya M.C., Barrera F.N., Prieto A., Gómez J., Mateu M.G., Neira J.L. The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: a biophysical characterization. Protein Science 2004, 13:1512-1523.
79. Ghosh R.K., Ghosh S.M., Chawla S. Recent advances in antiretroviral drugs. Expert Opinion on Pharmacotherapy 2011, 12:31-46.
80. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Analytical Biochemistry 1989, 182:319-326.
81. Gitti R.K., Lee B.M., Walker J., Summers M.F., Yoo S., Sundquist W.I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 1996, 273:231-235.
82. Goicochea N.L., Datta S.A.K., Ayaluru M., Kao C., Rein A., Dragnea B. Structure and stoichiometry of template-directed recombinant HIV-1 Gag particles. Journal of Molecular Biology 2011, 410:667-680.
83. Greene W.C., Debyser Z., Ikeda Y., Freed E.O., Stephens E., Yonemoto W., Buckheit R.W., Esté J.A., Cihlar T. Novel targets for HIV therapy. Antiviral Research 2008, 80:251-265.
84. Gross I., Hohenberg H., Kräusslich H.-G. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. European Journal of Biochemistry 1997, 249:592-600.
85. Gross I., Hohenberg H., Wilk T., Wiegers K., Grättlinger M., Müller B., Fuller S., Kräusslich H.-G. A conformational switch controlling HIV-1 morphogenesis. EMBO Journal 2000, 19:103-113.
86. Hilpert K., Behlke J., Scholz C., Misselwitz R., Schneider-Mergener J., Höhne W. Interaction of the capsid protein p24 (HIV-1) with sequence-derived peptides: influence on p24 dimerization. Virology 1999, 254:6-10.
87. Höglund S., Su J., Reneby S.S., Vegvari A., Hjerten S., Sintorn I.M., Foster H., Wu Y.P., Nystrom I., Vahlne A. Tripeptide interference with human immunodeficiency virus morphogenesis. Antimicrobial Agents and Chemotherapy 2002, 46:3597-3605.
88. Huseby D., Barklis R.L., Alfadhli A., Barklis E. Assembly of human immunodeficiency virus precursor gag proteins. Journal of Biological Chemistry 2005, 280:17664-17670.
89. Ivanov D., Tsodikov O.V., Kasanov J., Ellenberger T., Wagner G., Collins T. Domain-swapped dimerization of the HIV-1 capsid C-terminal domain. Proceedings of the National Academy of Sciences of United States of America 2007, 104:4353-4358.
90. Jeon Y.H., Lee J.Y., Kim S. Chemical modulators working at pharmacological interface of target proteins. Bioorganic and Medicinal Chemistry 2012, 10.1016/i.bmc.2011.12.016.
91. Jiang Y., Liu X., De Clercq E. New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle. Current Medicinal Chemistry 2011, 18:16-28.
92. Jin Y., Tan Z., He M., Tian B., Tang S., Hewlett I., Yang M. SAR and molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 CA. Bioorganic and Medicinal Chemistry 2010, 18:2135-2140.
93. Jouvenet N., Simon S.M., Bieniasz P.D. Visualizing HIV-1 assembly. Journal of Molecular Biology 2011, 410:501-511.
94. Kaushik-Basu N., Basu A., Harris D. Peptide inhibition of HIV-1. Biodrugs 2008, 22:161-175.
95. Kelley L.L., Momany C. Generation of a phagemid mouse recombinant antibody fragment library by multisite-directed mutagenesis. Biotechniques 2003, 35:750-752.
96. Kelly B.N., Howard B.R., Wang H., Robinson H., Sundquist W.I., Hill C.P. Implications for viral capsid assembly from crystal structures of HIV-1 Gag (1-278) and CA(N) (133-278). Biochemistry 2006, 45:11257-11266.
97. Kelly B.N., Kyere S., Kinde I., Tang C., Howard B.R., Robinson H., Sundquist W.I., Summers M.F., Hill C.P. Structure of the antiviral assembly inhibitor CAP-1 bound to the HIV-1 capsid protein. Journal of Molecular Biology 2007, 373:355-366.
98. Kim H.J., Eichinger A., Skerra A. High-affinity recognition of Lanthanide (III) Chelate Complexes by a Reprogrammed Human Lipocalin 2. Journal of the American Chemical Society 2009, 131:3565-3576.
99. Antiviral Strategies, Handbook of Experimental Pharmacology 2009, vol. 189. Springer-Verlag, Berlin.
100. Lanman J., Lam T.T., Barnes S., Sakalian M., Emmet M.R., Marshall A.G., Prevelige P.E. Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry. Journal of Molecular Biology 2003, 325:759-772.
101. Lanman J., Lamm T.T., Emmet M.R., Marshall A.G., Sakalian M., Prevelige P.E. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nature Structural & Molecular Biology 2004, 11:676-677.
102. Lanman J., Sexton J., Sakalian M., Prevelige P.E. Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro. Journal of Virology 2002, 76:6900-6908.
103. Lemke C.T., Titolo S., von Schwedler U., Goudreau N., Mercier J.-F., Wardrop E., Faucher A.-M., Coulombe R., Banik S.S.R., Fader L., Gagnon A., Kawai S.H., Rancourt J., Tremblay M., Yoakim C., Simoneau B., Archambault J., Sundquist W.I., Mason S.W. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein. Journal of Virology 2012, 86:6643-6655.
104. Li S., Hill C.P., Sundquist W.I., Finch J.T. Image reconstructions of helical assemblies of the HIV-1 capsid protein. Nature 2000, 407:409-413.
105. Li J., Tan Z., Tang S., Hewlett I., Pang R., He M., He S., Tian B., Chen K., Yang M. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclopyllin A to inhibit the assembly and uncoating of the viral capsid. Bioorganic and Medicinal Chemistry 2009, 17:3177-3188.
106. Li J., Tang S., Hewlett I., Yang M. HIV-1 capsid proteins and cyclophilin A as new targets for anti-AIDS therapeutic agents. Infectious Disorders-Drug Targets 2007, 7:238-244.
107. Mammano F., öhagen å., Höglund S., Göttlinger H.G. Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. Journal of Virology 1994, 68:4927-4936.
108. Mascarenhas A.P., Musier-Forsyth K. The capsid protein of human immunodeficiency virus: interactions of HIV-1 capsid with host protein factors. FEBS Journal 2009, 276:6118-6127.
109. Mateu M.G. Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Research 1995, 38:1-24.
110. Mateu M.G. Conformational stability of dimeric and monomeric forms of the C-terminal domain of human immunodeficiency virus-1 capsid protein. Journal of Molecular Biology 2002, 318:519-531.
111. Mateu M.G. The capsid protein of human immunodeficiency virus: intersubunit interactions during virus assembly. FEBS Journal 2009, 276:6098-6109.
112. Mateu M.G., Martínez M.A., Rocha E., Andreu D., Parejo J., Giralt E., Sobrino F., Domingo E. Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proceedings of the National Academy of Sciences of United States of America 1989, 86:5883-5887.
113. Mayo K., Huseby D., McDermott J., Arvidson B., Finlay L., Barklis E. Retrovirus capsid protein assembly arrangements. Journal of Molecular Biology 2003, 325:225-237.
114. Melby T., Westby M. Inhibitors of viral entry. Antiviral Strategies, Handbook of Experimental Pharmacology 2009, vol. 189:177-202. Springer-Verlag, Berlin.
115. Mészáros B., Simon I., Dosztány S. The expanding view of protein-protein interactions: complexes involving intrinsically disordered proteins. Physical Biology 2011, 8:035003.
116. Minton A.P. Macromolecular crowding and molecular recognition. Journal of Molecular Recognition 1993, 6:211-214.
117. Mirambeau, G. Darlix, J.-L., Summers, M.F., Berkhout, B. (Eds.), 2012. Special issue on Retroviral RNA, protein co-factors and chaperones. Virus Research.
118. Mirambeau G., Lyonnais S., Gorelick R.J. Features, processing states and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function. RNA Biology 2010, 7:724-734.
119. Momany C., Kovari L.C., Prongay A.J., Keller W., Gitti R.K., Lee B.M., Gorbalenya A.E., Tong L., McClure J., Ehrlich L.S., Summers M.F., Carter C., Rossmann M.G. Crystal structure of dimeric HIV-1 capsid protein. Natural Structural Biology 1996, 3:763-770.
120. Monroe E.B., Kang S., Kyere S.K., Li R., Prevelige P.E. Hydrogen/deuterium exchange analysis of HIV-1 capsid assembly and maturation. Structure 2010, 18:1483-1491.
121. Moreira I.S., Fernandes P.A., Ramos M.J. Hot spots-a review of the protein-protein interface determinant amino acid residues. Proteins 2007, 68:803-812.
122. Mori M., Manetti F., Botta M. Targeting protein-protein and protein-nucleic acid interactions for anti-HIV therapy. Current Pharmaceutical Design 2011, 17:3713-3728.
123. Mortuza G.B., Haire L.F., Stevens A., Smerdon S.J., Stoye J.P., Taylor I.A. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 2004, 431:481-485.
124. Muriaux D., Darlix J.-L. Properties and functions of the nucleocapsid protein in virus assembly. RNA Biology 2010, 7:744-753.
125. Muriaux D., Darlix J.-L., Cimarelli A. Targeting the assembly of the human immunodeficiency virus type 1. Current Pharmaceutical Design 2004, 10:3725-3739.
126. Nangola S., Urvoas A., Valerio-Lepiniec M., Khamaikawin W., Sakkhachornphop S., Hong S.S., Boulanger P., Minard P., Tayapiwatana C. Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein. Retrovirology 2012, 9:17.
127. Neira J.L. The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly. FEBS Journal 2009, 276:6110-6117.
128. Neira J.L. Biophysical and structural studies on the capsid protein of the human immunodeficiency virus type 1: a new drug target?. The Scientific World Journal 2009, 9:404-419.
129. Nermut M.V., Hockley D.J., Jowett J.B., Jones I.M., Garreau M., Thomas D. Fullerene-like organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 1994, 198:288-296.
130. Niedrig M., Gelderblom H.R., Pauli G., März J., Bickhard H., Wolf H., Modrow S. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. Journal of General Virology 1994, 75:1469-1974.
131. Pommier Y., Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nature Reviews 2012, 11:25-36.
132. Pornillos O., Ganser-Pornillos B.K., Banumathi S., Hua Y., Yeager M. Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. Journal of Molecular Biology 2010, 401:985-995.
133. Pornillos O., Ganser-Pornillos B.K., Kelly B.N., Hua Y., Whitby F.G., Stout C.D., Sundquist W.I., Hill C.P., Yeager M. X-ray structures of the hexameric building block of the HIV-1 capsid. Cell 2009, 137:1282-1292.
134. Pornillos O., Ganser-Pornillos B.K., Yeager M. Atomic-level modelling of the HIV capsid. Nature 2011, 469:424-428.
135. Prevelige, P. (inventor), 2006. Small molecule inhibitors of HIV-1 capsid assembly. U.S. Patent application number 20,090,176,776.
136. Prevelige P.E. New approaches for antiviral targeting of HIV assembly. Journal of Molecular Biology 2011, 410:634-640.
137. Purdy J.G., Flanagan J.M., Ropson I.J., Craven R.C. Retroviral capsid assembly: a role for the CA dimer in initiation. Journal of Molecular Biology 2009, 389:438-451.
138. Reguera J., Carreira A., Riolobos L., Almendral J.M., Mateu M.G. Role of interfacial residues in assembly, stability and conformation of a spherical viru capsid. Proceedings of the National Academy of Sciences of United States of America 2004, 101:2724-2729.
139. Reicin A.S., öhagen å., Yin L., Höglund S., Goff S.P. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. Journal of Virology 1996, 70:8645-8652.
140. Rein A., Datta S.A.K., Jones C.P., Musier-Forsyth K. Diverse interactions of retroviral Gag proteins with RNAs. Trends in Biochemical Sciences 2011, 36:373-380.
141. Rincón V., Bocanegra R., Rodríguez-Huete A., Rivas G., Mateu M.G. Effects of macromolecular crowding on the inhibition of virus assembly and virus-cell receptor recognition. Biophysical Journal 2011, 100:738-746.
142. Riolobos L., Reguera J., Mateu M.G., Almendral J.M. Nuclear transport of trimeric assembly intermediates exerts a morphogenetic control on the icosahedral parvovirus capsid. Journal of Molecular Biology 2006, 357:1026-1038.
143. Robert R., Jacobin-Valat M.-J., Daret D., Miraux S., Nurden A.T. Identification of human scFvs targeting atherosclerotic lesions. Selection by single round in vivo phage display. Journal of Biological Chemistry 2006, 281:40135-40143.
144. Salzwedel K., Martin D.E., Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Reviews 2007, 9:162-172.
145. Schlehuber S., Beste G., Skerra A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. Journal of Molecular Biology 2000, 297:1105-1120.
146. Shi J., Zhou J., Shah V.B., Aiken C., Whitby K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. Journal of Virology 2011, 85:542-549.
147. Shin R., Tzou Y.-M., Krishna N.R. Structure of a monomeric mutant of the HIV-1 capsid protein. Biochemistry 2011, 50:9457-9467.
148. Sticht J., Humbert M., Findlow S., Bodem J., Müller B., Dietrich U., Werner J., Kräusslich H.-G. A peptide inhibitor of HIV-1 assembly in vitro. Nature Structural & Molecular Biology 2005, 12:671-677.
149. Tang C., Loeliger E., Kinde I., Kyere S., Mayo K., Barklis E., Sun Y., Huang M., Summers M.F. Antiviral inhibition of the HIV-1 capsid protein. Journal of Molecular Biology 2003, 327:1013-1020.
150. Temsamani J., Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discovery Today 2004, 9:1012-1019.
151. Ternois F., Sticht J., Duquerroy S., Kräusslich H.-G., Rey F.A. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nature Structural & Molecular Biology 2005, 12:678-682.
152. Tian B., He M., Tang S., Hewlett I., Tan Z., Li J., Jin Y., Yang M. Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein. Bioorganic and Medicinal Chemistry Letters 2009, 19:2162-2167.
153. Valdes R., Ackers G.K. Study of protein subunit association equilibria by elution gel chromatography. Methods in Enzymology 1979, 61:125-142.
154. Valkov E., Sharpe T., Marsh M., Greive S., Hyvönen M. Targeting protein-protein interactions and fragment-based drug discovery. Topics in Current Chemistry 2012, 317:145-180.
155. Vogt V.M. Blocking HIV-1 virus assembly. Nature Structural & Molecular Biology 2005, 12:638-639.
156. von Schwedler U.K., Stemmler T.L., Klishko V.Y., Li S., Albertine K.H., Davis D.R., Sundquist W.I. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO Journal 1998, 17:1555-1568.
157. von Schwedler U.K., Stray K.M., Garrus J.E., Sundquist W.I. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. Journal of Virology 2003, 77:5439-5450.
158. Waheed A.A., Freed E.O. HIV type 1 gag as a target for antiviral therapy. AIDS Research and Human Retroviruses 2012, 28:54-75.
159. Wapling J., Srivastava S., Shehu-Xhilaga M., Tachedjian G. Targeting human immunodeficiency virus type 1 assembly, maturation and budding. Drug Target Insights 2007, 2:159-182.
160. Wilk T., Gross I., Gowen B.E., Rutten T., de Haas F., Welker R., Kräusslich H.-G., Boulanger P., Fuller S.D. Organization of immature human immunodeficiency virus type 1. Journal of Virology 2001, 75:759-771.
161. Wilson A.J. Inhibition of protein-protein interactions using designed molecules. Chemical Society Reviews 2009, 38:3289-3300.
162. Wong H.C., Shin R., Krishna N.R. Solution structure of a double mutant of the carboxy-terminal dimerization domain of the HIV-1 capsid protein. Biochemistry 2008, 47:2289-2297.
163. Worthylake D.K., Wang H., Yoo S., Sundquist W.I., Hill C.P. Structures of the HIV-1 capsid protein dimerization domain at 2.9 resolution. Acta Crystallographica 1999, D55:85-92.
164. Wright E.R., Schooler J.B., Ding H.J., Kieffer C., Filmore C., Sundquist W.I., Jensen G.J. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO Journal 2007, 26:2218-2226.
165. Yeager M. Design of in vitro symmetric complexes and analysis of hybrid methods reveal mechanisms of HIV capsid assembly. Journal of Molecular Biology 2011, 410:534-552.
166. Zhang H., Curreli F., Zhang X., Bhattacharya S., Waheed A.A., Cooper A., Cowburn D., Freed E.O., Debnath A.K. Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology 2011, 8:28.
167. Zhang H., Zhao Q., Bhattacharya S., Waheed A.A., Tong X., Hong A., Heck S., Curreli F., Goger M., Cowburn D., Freed E.O., Debnath A.K. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. Journal of Molecular Biology 2008, 378:565-580.
168. Zhang J., Liu X., De Clercq E. Capsid (CA) protein as a novel drug target: recent progress in the research of HIV-1 CA inhibitors. Mini-Reviews in Medicinal Chemistry 2009, 9:510-518.
169. Zhou H.X., Rivas G., Minton A.P. Macromolecular crowding and confinement: biochemical, biophysical and potential physiological consequences. Annual Review of Biophysics 2008, 37:375-397.